Professor Heather Payne is a Consultant Clinical Oncologist, specialising in urological and prostate cancer at University College London Hospitals NHS Trust and she also sees patients privately, including at The Harley Street Clinic and The Prostate Centre.

Professor Payne trained at St Mary’s Hospital and after qualifying, spent time in general medicine in London and Haiti.

On her returned to London, she trained as a Clinical Oncologist, and also developed an interest in urological oncology.

In addition to her clinical work, she is also actively involved in research, and she has pioneered a program of high-dose rate brachytherapy for prostate cancer. Current research interests include hormone therapy, sensitisation of hormones and radiotherapy, predictive indices for bowel toxicity with radiotherapy, proton beam therapy for prostate cancer, chemotherapy and assisting men with decision making and prostate cancer.

Professor Payne is principal investigator in a number of international and national studies and has been published in peer-reviewed journals. She is Chair of the British Uro-oncology Group and Oncology Lead for the National Prostate Cancer Audit. She also serves on the Prostate Cancer Advisory Group for the UK.

Dr Mulholland is a medical Oncologist who exclusively treats brain cancer at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre.He is also an honorary senior lecturer at UCL and a training programme director. 

His doctoral research was in genomic profiling in brain cancer at Cancer Research UK - this has led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally. 

He is a clinical lead in a European Consortium called Datrix, a multidisciplinary European collaboration to advance next-generation targeted hyperthermic cancer treatment for glioblastoma.

Dr Sarah Harris has been a Consultant Clinical Oncologist working at Guy’s and St Thomas’ NHS Trust for over 20 years. She now only sees patients privately at a range of private centres across London as well as by remote video consultation . Her areas of interests include breast cancer, prostate cancer and urological cancer, and she treats these conditions using radiotherapy and chemotherapy in central London and the south east of England.

She has extensive clinical experience in the management of breast cancer using radiotherapy and drug treatments. She has a specialist interest in technical radiotherapy due to its maximal benefits and reduced side effects. In particular she uses heart sparing radiotherapy techniques for left-sided breast radiotherapy. Furthermore, she regularly uses stereotactic radiotherapy for the treatment of localised recurrent cancers using the latest radiotherapy technologies, cyberknife and SABR. For the treatment of prostate cancer, she can perform external radiotherapy using modern IMRT and IGRT.

Along with her wealth of experience, she completed specialist training in proton beam radiotherapy at the University Of Pennsylvania in 2020. Dr Harris also holds many professional memberships, including the Royal College of Physicians and the Royal College of Radiologists.

In her leisure time , she is a keen golfer aspiring to a single figure handicap

Professor Paul Ellis is a Consultant Medical Oncologist based in London, UK. He has a specialist interest in research into novel therapies in breast cancer management was heavily involved in chairing the UK Dept. of Health Advisory committee on the introduction of Herceptin into UK clinical practise, co-authoring the national guidelines of its use.

After attaining his Medical Degree from Otago University, New Zealand he then moved to London to complete his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital. It was here he submitted his MD thesis on the biological predictors of response to primary chemotherapy. 

Professor Paul Ellis continues to take an active leadership role within the UK and European Clinical Trials community. He was the principal investigator and co-chair in the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been heavily involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including recently being Co-PI on the MARIANNE and KAMILLA trials. 

Dr Mary McCormack is a Consultant Clinical Oncologist, specialising in gynaecological andf breast cancers. She qualified in medicine from Guy's and St Thomas' Hospital. Before medical school, she undertook research in radiation biology and was awarded a PhD in 1989. Dr McCormack has worked in leading London cancer centres and in 2000, she was awarded the FRCR in clinical oncology. She was appointed a consultant at University College London Hospital in 2002.

Dr McCormack treats all subtypes of gynaecological cancer, including ovary, womb, uterus, cervix, vulva, vagina and also treats breast cancer. Treatments include chemotherapy, targeted/ biological therapy,radiotherapy and brachytherapy. She has a particular interest in cervical cancer treatment and targeted agents in breast, ovarian and endometrial cancer. Dr McCormack is a major contributor to national and international clinical trials and is the chief investigator on a nuber of studies. She is the current chair of the international Cervical Cancer Research Network (CCRN)and an exective member of the Gynaecologic Cancer Intergroup (GCIG)and a member of the International Gynaecologic Cancer Society's education committee.She is also a member of the ASCO International Affairs Committee

Dr Daniel Krell is a Consultant Oncologist, specialising in gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and neuroendocrine tumours. He is experienced in using chemotherapy, targeted therapy and immunotherapy. Dr Krell also manages patients with cancer of unknown primary and is the clinical lead for this. He works as a member of the multidisciplinary team for gastro-oesophageal and hepatobiliary cancer at the Royal Free Trust. He is also the clinical lead for Neuroendocrine tumour oncology at The Royal Free Hospital. 

He undertook oncology training at University College and the Royal Free Hospitals in London. In addition to his primary medical degree, he also gained a Bachelor’s degree in immunology and microbiology, in addition to a DPhil in Clinical Medicine at the University of Oxford’s Wellcome Trust Centre for Human Genetics and was funded by Cancer Research UK and HCA. His research involved the design of models to investigate the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer. This may help identify new therapeutic targets in this area. Dr Krell continues to be involved in clinical research and trials aimed at identifying new cancer therapies, focused on gastrointestinal, hepatobiliary and neuroendocrine tumours. He has published a number of peer-reviewed papaers and presented at national and international conferences.

Dr Constantine Alifrangis is a Consultant Medical Oncologist in London. He specialises in the treatment of urological cancers including prostate, bladder, testicular and penile cancer.

He graduated from Guys’ Kings and St Thomas’ Medical school and was awarded the University Gold Medal for medicine. Following this, he completed his postgraduate medical training in oncology at Imperial College London. He undertook research into advanced prostate cancer at Hammersmith Hospital, and was awarded a Wellcome Trust fellowship to research the link between cancer genetics and the efficacy of novel therapies. He was awarded a PhD by the University of Cambridge in 2014 for this work. He was also awarded the Sylvia Lawler prize by the Oncology section of the Royal Society of Medicine.

In 2016, he was appointed Consultant Medical Oncologist at University College London Hospital and St Bartholomew’s. He is the Lead Oncologist for Testicular Cancer, treating patients with advanced prostate cancer and is part of a specialist team looking after patients with penile cancer.

He is actively involved in research into the genetic basis of cancer and drug resistance, including personalised approaches to cancer treatment. He is also the Lead Investigator for number of clinical studies looking at rarer and understudied cancers. He has presented his research at a number of international conferences and published research in various cancer journals including the Lancet, Journal of Clinical Oncology, and Clinical Cancer Research.

Professor Peter Schmid is the Clinical Director of the St. Bartholomew Breast Cancer Centre, and Honorary Consultant Medical Oncologist and lead of the Cancer Immune Therapy group at Barts Hospital. He is also Professor of Cancer Medicine and Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute.

Professor Schmid studied medicine in Munich and Aberdeen. He was awarded scholarships by the German National Academic Foundation, the German Academic Exchange Service and the Hanns-Seidel-Foundation. Following this he completed specialist training in internal medicine, medical oncology and haematology in Berlin. Subsequently he undertook an MD in Clinical Chemistry at the Technical University Munich and a PhD in Medical Oncology at the Charité University in Berlin. In 2005, Professor Schmid moved to the UK and was appointed as Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. He was subsequently made Foundation Chair in Cancer Medicine at the University of Sussex.

He specialises in breast cancer, lung cancer and cancer immune therapy and is renowned internationally for this work in cancer immunotherapy. He was instrumental in the formation of the Cancer Immune Therapy group at Barts Hospital, which has become recognised globally as a leader in this field.

Professor Schmid has a particular research interest in triple negative breast cancer and endocrine resistance and has led more than 20 clinical studies and several translational research programmes in these areas. He also has an interest in personalised cancer medicine using novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. He currently leads an international group to establish blood-based circulating biomarkers.

He has authored or co-authored more than 150 publications and has published a book on the management of bone metastases. He is also regularly invited to speak at major international cancer conferences. Professor Schmid is a member of the breast cancer faculty of the European Society of Medical Oncology and has chaired several medical research committees. He was awarded the Breast Cancer Research Award 2012 by German Patient group Mammazone.

Professor Schmid has a strong interest in patient-doctor communication, for a number of years, he ran a programme training oncologists and oncology nurses in communication.

Dr Beatrice Seddon is consultant on the Sarcoma Unit at University College Hospital, which together with the Bone Tumour Unit at the Royal National Orthopaedic Hospital, comprises the London Bone and Soft Tissue Tumour Service.

Dr Seddon trained in treating sarcomas at the Royal Marsden and Middlesex Hospitals in London, and now specialises exclusively in the treatment of soft tissue and bone sarcomas with chemotherapy and radiotherapy.

She completed her PhD (University of London) at the Institute of Cancer Research in imaging of tumour hypoxia, and currently has a strong interest in clinical trials in sarcoma, acting as principal and chief investigator for a number of national and international trials. She is actively involved in coordinating sarcoma research at a national level as a member of the NCRN Sarcoma Clinical Studies Group, and is also a member of the EORTC Soft Tissue and Bone Sarcoma Group. She regularly teaches and lectures on the management of sarcomas.

Dr Alison Jones is a Consultant Medical Oncologist based at the Royal Free Hospital and University College Hospital, London, where she works as the clinical lead. 

Dr Jones has a specialist interest in the diagnosis and management of patients who suffer from breast cancer. She also focuses on young patients who are diagnosed with breast cancer. She is on the steering committee for numberous cancer trials within the UK, paying interest to the introduction of new drugs and personalised medicines. 

After graduating from Bristol University in 1980, Dr Jones went on to specialise in Medical Oncology and completed her training at The Royal Marsden Hospital. Her MD Thesis was conducted at the Institute of Cancer Research.

She is chair of the Breast Cancer Tumour Board responsible for creating guidelines as well as introducing new drug procedures. In 2006 she became Chair of the Association of Cancer Physicians of the UK. She sees private patients in her clinic in Harley Street.